financetom
Business
financetom
/
Business
/
US Steel Reports Better-Than-Expected Q3 Results, Aims To Close Nippon Steel Deal By Year End
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US Steel Reports Better-Than-Expected Q3 Results, Aims To Close Nippon Steel Deal By Year End
Nov 4, 2024 11:45 AM

United States Steel Corporation ( X ) reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report.  

The Details: U.S. Steel reported quarterly earnings of 56 cents per share which beat the analyst consensus estimate of 47 cents. Quarterly revenue came in at $3.85 billion, which beat the consensus estimate of $3.77 billion.

U.S. Steel said it will continue to work to close the deal with Nippon Steel by the year’s end.

Read Next: Reddit ‘Remains A Favorite’ For Wall Street After ‘Emphatic Beat And Raise’ In Q3

“Third quarter adjusted EBITDA of $319 million demonstrated resilience in our business model despite the weaker average selling prices experienced across our operating segments. The North American Flat-Rolled segment continued to benefit from a strong commercial strategy that leveraged a diverse product mix and a purposeful increase in contracted volumes across the end markets we serve,” said U. S. Steel CEO David B. Burritt.

Outlook: U.S. Steel said it expects fourth-quarter adjusted EBITDA in the range of $225 million to $275 million.

X Price Action: According to Benzinga Pro, U.S. Steel shares are down 0.90% after-hours at $38.50 at the time of publication Thursday.

Read Also: 

Starbucks Analysts Bullish On CEO Brian Niccol After Tough Preannouncement: ‘Zeroing In’ On Right Issues

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Medtronic Says FDA Approved Transcatheter Aortic Valve Replacement System for Heart Valve Disease
Medtronic Says FDA Approved Transcatheter Aortic Valve Replacement System for Heart Valve Disease
Mar 27, 2024
10:15 AM EDT, 03/27/2024 (MT Newswires) -- Medtronic ( MDT ) said Wednesday that the US Food and Drug Administration approved its transcatheter aortic valve replacement system to treat symptomatic severe aortic stenosis, a heart valve disease. The company said the Evolut FX, slated to launch this summer, is approved for all risk categories in the US. Shares of the...
N-able Introduces Cloud Commander for Managed Services Providers' Microsoft Cloud Management
N-able Introduces Cloud Commander for Managed Services Providers' Microsoft Cloud Management
Mar 27, 2024
10:13 AM EDT, 03/27/2024 (MT Newswires) -- N-able (NABL) on Wednesday introduced N-able Cloud Commander, which helps managed services providers to manage, secure and automate Microsoft's (MSFT) Microsoft 365, Azure and Intune in a single console. Cloud Commander also plans to add Windows 365 management capabilities, the company said. Price: 12.99, Change: +0.05, Percent Change: +0.39 ...
CGI Gets $162 Million Contract From UK Government's Cabinet Office
CGI Gets $162 Million Contract From UK Government's Cabinet Office
Mar 27, 2024
10:16 AM EDT, 03/27/2024 (MT Newswires) -- CGI (GIB) said Wednesday it will work with the cabinet office digital department of the UK government to deliver various services and products under a five-year contract valued at $162 million. The information technology and business consulting services firm said the move will support the digital transformation of the cabinet office's business units....
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Mar 27, 2024
Wednesday, Novocure Ltd ( NVCR ) released data from the Phase 3 METIS clinical trial of Tumor Treating Fields (TTFields) therapy. The study met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial (within skull/brain) progression for adult patients treated with TTFields therapy and supportive care compared to supportive care alone for 1-10 brain metastases from non-small cell lung cancer...
Copyright 2023-2026 - www.financetom.com All Rights Reserved